September 02, 2025 17:00 ET | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc.…
August 28, 2025 19:30 ET | Source: Eagle Pharmaceuticals, Inc. WOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle…
PALO ALTO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative…
WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced…
August 15, 2025 16:05 ET | Source: X4 Pharmaceuticals BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a…
Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in…
AHMEDABAD, India, Aug. 6, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has…
AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ -- Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for…
August 01, 2025 16:55 ET | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE)…
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom)…